JP2003512467A - チアゾールおよびイミダゾ（４，５−ｂ）ピリジン化合物ならびにそれらの医薬用途 - Google Patents
チアゾールおよびイミダゾ（４，５−ｂ）ピリジン化合物ならびにそれらの医薬用途Info
- Publication number
- JP2003512467A JP2003512467A JP2001533132A JP2001533132A JP2003512467A JP 2003512467 A JP2003512467 A JP 2003512467A JP 2001533132 A JP2001533132 A JP 2001533132A JP 2001533132 A JP2001533132 A JP 2001533132A JP 2003512467 A JP2003512467 A JP 2003512467A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally
- substituted
- fluorophenyl
- pyrimidinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical class C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 title claims description 34
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 title description 3
- 239000002253 acid Substances 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 150000002148 esters Chemical class 0.000 claims abstract description 18
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 14
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 108
- -1 Each Halo Chemical group 0.000 claims description 101
- 239000000126 substance Substances 0.000 claims description 85
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 70
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 50
- 229910052736 halogen Inorganic materials 0.000 claims description 41
- 150000002367 halogens Chemical class 0.000 claims description 41
- 229910052757 nitrogen Inorganic materials 0.000 claims description 41
- 125000001424 substituent group Chemical group 0.000 claims description 37
- 125000005842 heteroatom Chemical group 0.000 claims description 34
- 229910052717 sulfur Inorganic materials 0.000 claims description 34
- 229910052760 oxygen Inorganic materials 0.000 claims description 32
- 125000003118 aryl group Chemical group 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 125000006413 ring segment Chemical group 0.000 claims description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 125000001072 heteroaryl group Chemical group 0.000 claims description 19
- 239000002243 precursor Substances 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 17
- 125000005843 halogen group Chemical group 0.000 claims description 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 15
- 150000001412 amines Chemical class 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 125000004076 pyridyl group Chemical group 0.000 claims description 12
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 10
- 230000001363 autoimmune Effects 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 208000027866 inflammatory disease Diseases 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 8
- 238000005859 coupling reaction Methods 0.000 claims description 7
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 6
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
- 150000007942 carboxylates Chemical class 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- 230000008878 coupling Effects 0.000 claims description 6
- 238000010168 coupling process Methods 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 6
- 239000003018 immunosuppressive agent Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 5
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 claims description 5
- 125000004193 piperazinyl group Chemical group 0.000 claims description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- ICHINRNOSJBRCE-HNNXBMFYSA-N 2-(4-fluorophenyl)-1-[2-[[(1s)-1-phenylethyl]amino]pyrimidin-4-yl]imidazo[4,5-b]pyridin-5-amine Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(N=1)=NC=CC=1N(C1=CC=C(N)N=C1N=1)C=1C1=CC=C(F)C=C1 ICHINRNOSJBRCE-HNNXBMFYSA-N 0.000 claims description 4
- XUQRICHQPSQKSS-FQEVSTJZSA-N 4-[2-(4-fluorophenyl)-5-(4-methylpiperazin-1-yl)imidazo[4,5-b]pyridin-1-yl]-n-[(1s)-1-phenylethyl]pyrimidin-2-amine Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(N=1)=NC=CC=1N(C1=CC=2)C(C=3C=CC(F)=CC=3)=NC1=NC=2N1CCN(C)CC1 XUQRICHQPSQKSS-FQEVSTJZSA-N 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 125000001091 aminosulfinyl group Chemical class [H]N([H])S(*)=O 0.000 claims description 4
- 125000004682 aminothiocarbonyl group Chemical class NC(=S)* 0.000 claims description 4
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims description 4
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 4
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 4
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- GFJQCVZKRHKDIX-UHFFFAOYSA-N n-cyclopentyl-4-[2-(4-fluorophenyl)-5-pyridin-4-ylimidazo[4,5-b]pyridin-1-yl]pyrimidin-2-amine Chemical compound C1=CC(F)=CC=C1C1=NC2=NC(C=3C=CN=CC=3)=CC=C2N1C1=CC=NC(NC2CCCC2)=N1 GFJQCVZKRHKDIX-UHFFFAOYSA-N 0.000 claims description 4
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims description 4
- 125000005936 piperidyl group Chemical group 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 125000004953 trihalomethyl group Chemical group 0.000 claims description 4
- QWLKXLNJJRBNII-UHFFFAOYSA-N 1-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-fluorophenyl)imidazo[4,5-b]pyridin-5-amine Chemical compound N=1C2=NC(N)=CC=C2N(C=2N=C(NC3CCCC3)N=CC=2)C=1C1=CC=C(F)C=C1 QWLKXLNJJRBNII-UHFFFAOYSA-N 0.000 claims description 3
- HQYTZGXGJITFDL-UHFFFAOYSA-N 1-[2-(cyclopentylamino)pyrimidin-4-yl]-n-(3-fluorophenyl)-2-(4-fluorophenyl)imidazo[4,5-b]pyridin-5-amine Chemical compound C1=CC(F)=CC=C1C1=NC2=NC(NC=3C=C(F)C=CC=3)=CC=C2N1C1=CC=NC(NC2CCCC2)=N1 HQYTZGXGJITFDL-UHFFFAOYSA-N 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 238000006254 arylation reaction Methods 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- MGIUUUFXHGZVRO-UHFFFAOYSA-N n-benzyl-1-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-fluorophenyl)imidazo[4,5-b]pyridin-5-amine Chemical compound C1=CC(F)=CC=C1C1=NC2=NC(NCC=3C=CC=CC=3)=CC=C2N1C1=CC=NC(NC2CCCC2)=N1 MGIUUUFXHGZVRO-UHFFFAOYSA-N 0.000 claims description 3
- UBTOWEAWXVZTQD-UHFFFAOYSA-N n-cyclobutyl-4-[2-(4-fluorophenyl)-5-(4-methylpiperazin-1-yl)imidazo[4,5-b]pyridin-1-yl]pyrimidin-2-amine Chemical compound C1CN(C)CCN1C1=CC=C(N(C(=N2)C=3C=CC(F)=CC=3)C=3N=C(NC4CCC4)N=CC=3)C2=N1 UBTOWEAWXVZTQD-UHFFFAOYSA-N 0.000 claims description 3
- DESTZNVBBLDULL-UHFFFAOYSA-N n-cyclopentyl-4-[2-(4-fluorophenyl)-5-(1-methylpiperidin-4-yl)imidazo[4,5-b]pyridin-1-yl]pyrimidin-2-amine Chemical compound C1CN(C)CCC1C1=CC=C(N(C(=N2)C=3C=CC(F)=CC=3)C=3N=C(NC4CCCC4)N=CC=3)C2=N1 DESTZNVBBLDULL-UHFFFAOYSA-N 0.000 claims description 3
- BARFMAOTOPEJFY-UHFFFAOYSA-N n-cyclopentyl-4-[2-(4-fluorophenyl)-5-(4-methylpiperazin-1-yl)imidazo[4,5-b]pyridin-1-yl]pyrimidin-2-amine Chemical compound C1CN(C)CCN1C1=CC=C(N(C(=N2)C=3C=CC(F)=CC=3)C=3N=C(NC4CCCC4)N=CC=3)C2=N1 BARFMAOTOPEJFY-UHFFFAOYSA-N 0.000 claims description 3
- YGDCPBYTBSIICB-UHFFFAOYSA-N n-cyclopentyl-4-[2-(4-fluorophenyl)-5-morpholin-4-ylimidazo[4,5-b]pyridin-1-yl]pyrimidin-2-amine Chemical compound C1=CC(F)=CC=C1C1=NC2=NC(N3CCOCC3)=CC=C2N1C1=CC=NC(NC2CCCC2)=N1 YGDCPBYTBSIICB-UHFFFAOYSA-N 0.000 claims description 3
- CMDWMHFRSWQQAO-UHFFFAOYSA-N n-cyclopentyl-4-[2-(4-fluorophenyl)-5-pyridin-3-ylimidazo[4,5-b]pyridin-1-yl]pyrimidin-2-amine Chemical compound C1=CC(F)=CC=C1C1=NC2=NC(C=3C=NC=CC=3)=CC=C2N1C1=CC=NC(NC2CCCC2)=N1 CMDWMHFRSWQQAO-UHFFFAOYSA-N 0.000 claims description 3
- WRFUMBPRGLYOAV-UHFFFAOYSA-N n-cyclopropyl-4-[2-(4-fluorophenyl)-5-(4-methylpiperazin-1-yl)imidazo[4,5-b]pyridin-1-yl]pyrimidin-2-amine Chemical compound C1CN(C)CCN1C1=CC=C(N(C(=N2)C=3C=CC(F)=CC=3)C=3N=C(NC4CC4)N=CC=3)C2=N1 WRFUMBPRGLYOAV-UHFFFAOYSA-N 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 3
- 229920002554 vinyl polymer Polymers 0.000 claims description 3
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 claims description 2
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 230000001861 immunosuppressant effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 12
- 125000000027 (C1-C10) alkoxy group Chemical class 0.000 claims 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- MJMDLUIORMBKHA-IBGZPJMESA-N 4-[4-(4-fluorophenyl)-2-(4-methylpiperidin-1-yl)-1,3-thiazol-5-yl]-n-[(1s)-1-phenylethyl]pyrimidin-2-amine Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(N=1)=NC=CC=1C=1SC(N2CCC(C)CC2)=NC=1C1=CC=C(F)C=C1 MJMDLUIORMBKHA-IBGZPJMESA-N 0.000 claims 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
- 241001274216 Naso Species 0.000 claims 1
- 150000003973 alkyl amines Chemical class 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical class NS(=O)(=O)* 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 claims 1
- OONDROKXCHJESN-UHFFFAOYSA-N n-(cyclopropylmethyl)-4-[4-(4-fluorophenyl)-2-(4-methylpiperidin-1-yl)-1,3-thiazol-5-yl]pyridin-2-amine Chemical compound C1CC(C)CCN1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=C(NCC3CC3)N=CC=2)S1 OONDROKXCHJESN-UHFFFAOYSA-N 0.000 claims 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 abstract description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 4
- 108010002352 Interleukin-1 Proteins 0.000 abstract description 3
- 208000001132 Osteoporosis Diseases 0.000 abstract description 3
- 210000000988 bone and bone Anatomy 0.000 abstract description 3
- 208000030159 metabolic disease Diseases 0.000 abstract description 3
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 66
- 238000005160 1H NMR spectroscopy Methods 0.000 description 53
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 42
- 239000011734 sodium Substances 0.000 description 42
- 239000003795 chemical substances by application Substances 0.000 description 35
- 239000011541 reaction mixture Substances 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 28
- 239000012074 organic phase Substances 0.000 description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 23
- 229910004298 SiO 2 Inorganic materials 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 18
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 18
- 238000004587 chromatography analysis Methods 0.000 description 17
- 239000013078 crystal Substances 0.000 description 17
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- 102100040247 Tumor necrosis factor Human genes 0.000 description 14
- 239000006260 foam Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- 229910004373 HOAc Inorganic materials 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 7
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000008096 xylene Substances 0.000 description 6
- DUDMVOWQHOVBIJ-UHFFFAOYSA-N 4-[5-chloro-2-(4-fluorophenyl)imidazo[4,5-b]pyridin-1-yl]-n-cyclopentylpyrimidin-2-amine Chemical compound C1=CC(F)=CC=C1C1=NC2=NC(Cl)=CC=C2N1C1=CC=NC(NC2CCCC2)=N1 DUDMVOWQHOVBIJ-UHFFFAOYSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- BBYDXOIZLAWGSL-UHFFFAOYSA-N 4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1 BBYDXOIZLAWGSL-UHFFFAOYSA-N 0.000 description 4
- SECBGKYJKCNDID-UHFFFAOYSA-N 4-iodo-2-methylsulfanylpyrimidine Chemical compound CSC1=NC=CC(I)=N1 SECBGKYJKCNDID-UHFFFAOYSA-N 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 4
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 238000001896 rotating frame Overhauser effect spectroscopy Methods 0.000 description 4
- 239000012047 saturated solution Substances 0.000 description 4
- RQEUFEKYXDPUSK-ZETCQYMHSA-N (1S)-1-phenylethanamine Chemical compound C[C@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-ZETCQYMHSA-N 0.000 description 3
- QCNCMKGQOCQRNB-KRWDZBQOSA-N 4-[4-(4-fluorophenyl)-2-piperidin-4-yl-1,3-thiazol-5-yl]-n-[(1s)-1-phenylethyl]pyrimidin-2-amine Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(N=1)=NC=CC=1C=1SC(C2CCNCC2)=NC=1C1=CC=C(F)C=C1 QCNCMKGQOCQRNB-KRWDZBQOSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 101150003085 Pdcl gene Proteins 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- UTZCWVSFOGAZLW-UHFFFAOYSA-N ethyl n-(piperidine-4-carbothioyl)carbamate Chemical compound CCOC(=O)NC(=S)C1CCNCC1 UTZCWVSFOGAZLW-UHFFFAOYSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229920000137 polyphosphoric acid Polymers 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 150000003462 sulfoxides Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- UWNDUYAKSCWHDG-UHFFFAOYSA-N 2-(2,4-difluoro-3h-pyridin-4-yl)-1-phenylethanone Chemical compound C1C(F)=NC=CC1(F)CC(=O)C1=CC=CC=C1 UWNDUYAKSCWHDG-UHFFFAOYSA-N 0.000 description 2
- HEAHTFNRCPDZFZ-UHFFFAOYSA-N 2-(4-fluoro-2-methylsulfanyl-1h-pyrimidin-4-yl)-1-phenylethanone Chemical compound C1=CNC(SC)=NC1(F)CC(=O)C1=CC=CC=C1 HEAHTFNRCPDZFZ-UHFFFAOYSA-N 0.000 description 2
- LFQGFCBASJKNFJ-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-(2-methylsulfanylpyrimidin-4-yl)imidazo[4,5-b]pyridin-5-amine Chemical compound CSC1=NC=CC(N2C3=CC=C(N)N=C3N=C2C=2C=CC(F)=CC=2)=N1 LFQGFCBASJKNFJ-UHFFFAOYSA-N 0.000 description 2
- BBSVLZNTKDLFJM-UHFFFAOYSA-N 2-(4-fluorophenyl)-1h-imidazo[4,5-b]pyridin-5-amine Chemical compound N=1C2=NC(N)=CC=C2NC=1C1=CC=C(F)C=C1 BBSVLZNTKDLFJM-UHFFFAOYSA-N 0.000 description 2
- CGEYWOCSYFPNQC-SFHVURJKSA-N 4-[4-(4-fluorophenyl)-2-piperidin-4-yl-1,3-thiazol-5-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(N=CC=1)=CC=1C=1SC(C2CCNCC2)=NC=1C1=CC=C(F)C=C1 CGEYWOCSYFPNQC-SFHVURJKSA-N 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- DSUFRPVVBZLHPI-UHFFFAOYSA-N 4-fluoro-n-methoxy-n-methylbenzamide Chemical compound CON(C)C(=O)C1=CC=C(F)C=C1 DSUFRPVVBZLHPI-UHFFFAOYSA-N 0.000 description 2
- LQIBDQRNVCKDTM-UHFFFAOYSA-N 5-chloro-2-(4-fluorophenyl)-1-(2-methylsulfanylpyrimidin-4-yl)imidazo[4,5-b]pyridine Chemical compound CSC1=NC=CC(N2C3=CC=C(Cl)N=C3N=C2C=2C=CC(F)=CC=2)=N1 LQIBDQRNVCKDTM-UHFFFAOYSA-N 0.000 description 2
- YXEOOPSAHBBSOZ-UHFFFAOYSA-N 5-chloro-2-(4-fluorophenyl)-1-(2-methylsulfinylpyrimidin-4-yl)imidazo[4,5-b]pyridine Chemical compound CS(=O)C1=NC=CC(N2C3=CC=C(Cl)N=C3N=C2C=2C=CC(F)=CC=2)=N1 YXEOOPSAHBBSOZ-UHFFFAOYSA-N 0.000 description 2
- HALLIODPNPMRCZ-UHFFFAOYSA-N 5-chloro-2-(4-fluorophenyl)-1h-imidazo[4,5-b]pyridine Chemical compound C1=CC(F)=CC=C1C1=NC2=NC(Cl)=CC=C2N1 HALLIODPNPMRCZ-UHFFFAOYSA-N 0.000 description 2
- QEIRYIILFUVXAM-UHFFFAOYSA-N 6-chloropyridine-2,3-diamine Chemical compound NC1=CC=C(Cl)N=C1N QEIRYIILFUVXAM-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- XOXCFWMBFDUFRD-UHFFFAOYSA-N CS(=O)C1=NC=CC(C=2SC=CN=2)=N1 Chemical compound CS(=O)C1=NC=CC(C=2SC=CN=2)=N1 XOXCFWMBFDUFRD-UHFFFAOYSA-N 0.000 description 2
- AFFTZDYHTGEWFH-UHFFFAOYSA-N CSC1=NC=CC(C=2SC=CN=2)=N1 Chemical compound CSC1=NC=CC(C=2SC=CN=2)=N1 AFFTZDYHTGEWFH-UHFFFAOYSA-N 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 2
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229910052681 coesite Inorganic materials 0.000 description 2
- 229910052906 cristobalite Inorganic materials 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- BNLOJIFCLRBOOP-UHFFFAOYSA-N ethyl 4-(5,6-diaminopyridin-2-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C1=CC=C(N)C(N)=N1 BNLOJIFCLRBOOP-UHFFFAOYSA-N 0.000 description 2
- DJAXTDZUKOLBEV-UHFFFAOYSA-N ethyl 4-(6-amino-5-nitropyridin-2-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C1=CC=C([N+]([O-])=O)C(N)=N1 DJAXTDZUKOLBEV-UHFFFAOYSA-N 0.000 description 2
- FYRVEFPNRHDRRT-UHFFFAOYSA-N ethyl 4-[4-(4-fluorophenyl)-5-(2-fluoropyridin-4-yl)-1,3-thiazol-2-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=C(F)N=CC=2)S1 FYRVEFPNRHDRRT-UHFFFAOYSA-N 0.000 description 2
- YADBJAFZFKRMAF-FQEVSTJZSA-N ethyl 4-[4-(4-fluorophenyl)-5-[2-[[(1s)-1-phenylethyl]amino]pyridin-4-yl]-1,3-thiazol-2-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=C(N[C@@H](C)C=3C=CC=CC=3)N=CC=2)S1 YADBJAFZFKRMAF-FQEVSTJZSA-N 0.000 description 2
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 150000005232 imidazopyridines Chemical class 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- JXGOYHRNCBAFKB-UHFFFAOYSA-N n-cyclopentyl-4-[5-ethenyl-2-(4-fluorophenyl)imidazo[4,5-b]pyridin-1-yl]pyrimidin-2-amine Chemical compound C1=CC(F)=CC=C1C1=NC2=NC(C=C)=CC=C2N1C1=CC=NC(NC2CCCC2)=N1 JXGOYHRNCBAFKB-UHFFFAOYSA-N 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229910052682 stishovite Inorganic materials 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- DTQSULIFIFLCMJ-UHFFFAOYSA-N tert-butyl 4-[2-(4-fluorophenyl)-1h-imidazo[4,5-b]pyridin-5-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(NC(=N2)C=3C=CC(F)=CC=3)C2=N1 DTQSULIFIFLCMJ-UHFFFAOYSA-N 0.000 description 2
- 150000003557 thiazoles Chemical class 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QIWRFOJWQSSRJZ-UHFFFAOYSA-N tributyl(ethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C=C QIWRFOJWQSSRJZ-UHFFFAOYSA-N 0.000 description 2
- 229910052905 tridymite Inorganic materials 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- 230000006433 tumor necrosis factor production Effects 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- ZDPAWHACYDRYIW-UHFFFAOYSA-N 1-(4-fluorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(F)C=C1 ZDPAWHACYDRYIW-UHFFFAOYSA-N 0.000 description 1
- GELKGHVAFRCJNA-UHFFFAOYSA-N 2,2-Dimethyloxirane Chemical compound CC1(C)CO1 GELKGHVAFRCJNA-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QSIBNTMXHTWXMV-UHFFFAOYSA-N 2-bromo-1-(4-fluorophenyl)-2-(2-fluoropyridin-4-yl)ethanone Chemical compound C1=CC(F)=CC=C1C(=O)C(Br)C1=CC=NC(F)=C1 QSIBNTMXHTWXMV-UHFFFAOYSA-N 0.000 description 1
- YDIGVDUIMDDIRI-UHFFFAOYSA-N 2-bromo-2-(2,4-difluoro-3h-pyridin-4-yl)-1-phenylethanone Chemical compound C1C(F)=NC=CC1(F)C(Br)C(=O)C1=CC=CC=C1 YDIGVDUIMDDIRI-UHFFFAOYSA-N 0.000 description 1
- CQUDIDJBJLLTLY-UHFFFAOYSA-N 2-bromo-2-(4-fluoro-2-methylsulfanyl-1h-pyrimidin-4-yl)-1-phenylethanone Chemical compound C1=CNC(SC)=NC1(F)C(Br)C(=O)C1=CC=CC=C1 CQUDIDJBJLLTLY-UHFFFAOYSA-N 0.000 description 1
- ZBFAXMKJADVOGH-UHFFFAOYSA-N 2-fluoro-4-methylpyridine Chemical compound CC1=CC=NC(F)=C1 ZBFAXMKJADVOGH-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- HJEPFPDXSFKWQH-IBGZPJMESA-N 4-[4-(4-fluorophenyl)-2-(1-methylpiperidin-4-yl)-1,3-thiazol-5-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(N=CC=1)=CC=1C=1SC(C2CCN(C)CC2)=NC=1C1=CC=C(F)C=C1 HJEPFPDXSFKWQH-IBGZPJMESA-N 0.000 description 1
- KFKODKNJGWITBQ-SFHVURJKSA-N 4-[4-(4-fluorophenyl)-2-(1-methylpiperidin-4-yl)-1,3-thiazol-5-yl]-n-[(1s)-1-phenylethyl]pyrimidin-2-amine Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(N=1)=NC=CC=1C=1SC(C2CCN(C)CC2)=NC=1C1=CC=C(F)C=C1 KFKODKNJGWITBQ-SFHVURJKSA-N 0.000 description 1
- MTSMVADXHUTRBK-UHFFFAOYSA-N 4-iodo-2-methylpyrimidine Chemical compound CC1=NC=CC(I)=N1 MTSMVADXHUTRBK-UHFFFAOYSA-N 0.000 description 1
- UCERVHYBSTYCQS-UHFFFAOYSA-N 4-methyl-2-methylsulfanylpyrimidine Chemical compound CSC1=NC=CC(C)=N1 UCERVHYBSTYCQS-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- UWUBPQVLQOHMKF-UHFFFAOYSA-N 5-chloro-1h-imidazo[4,5-b]pyridine Chemical compound ClC1=CC=C2NC=NC2=N1 UWUBPQVLQOHMKF-UHFFFAOYSA-N 0.000 description 1
- WERABQRUGJIMKQ-UHFFFAOYSA-N 6-chloro-3-nitropyridin-2-amine Chemical compound NC1=NC(Cl)=CC=C1[N+]([O-])=O WERABQRUGJIMKQ-UHFFFAOYSA-N 0.000 description 1
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 101100026251 Caenorhabditis elegans atf-2 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 101000651310 Desulfitobacterium hafniense (strain Y51) Trigger factor 2 Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010049466 Erythroblastosis Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 238000011795 OF1 mouse Methods 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
- 150000008062 acetophenones Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 235000012206 bottled water Nutrition 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001715 carbamic acids Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- WYBUJWLYYDAQAJ-IBGZPJMESA-N ethyl 4-[4-(4-fluorophenyl)-5-[2-[[(1s)-1-phenylethyl]amino]pyrimidin-4-yl]-1,3-thiazol-2-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1C1=NC(C=2C=CC(F)=CC=2)=C(C=2N=C(N[C@@H](C)C=3C=CC=CC=3)N=CC=2)S1 WYBUJWLYYDAQAJ-IBGZPJMESA-N 0.000 description 1
- MDHWSNVTHKVSCU-UHFFFAOYSA-N ethyl n-(piperidine-4-carbonyl)carbamate Chemical compound CCOC(=O)NC(=O)C1CCNCC1 MDHWSNVTHKVSCU-UHFFFAOYSA-N 0.000 description 1
- LNOQURRKNJKKBU-UHFFFAOYSA-N ethyl piperazine-1-carboxylate Chemical compound CCOC(=O)N1CCNCC1 LNOQURRKNJKKBU-UHFFFAOYSA-N 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 208000016036 idiopathic nephrotic syndrome Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- TYHALPCMJPGQFF-UHFFFAOYSA-N n-cyclopentyl-4-[2-(4-fluorophenyl)-5-piperidin-4-ylimidazo[4,5-b]pyridin-1-yl]pyrimidin-2-amine Chemical compound C1=CC(F)=CC=C1C1=NC2=NC(C3CCNCC3)=CC=C2N1C1=CC=NC(NC2CCCC2)=N1 TYHALPCMJPGQFF-UHFFFAOYSA-N 0.000 description 1
- NCCHARWOCKOHIH-UHFFFAOYSA-N n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1 NCCHARWOCKOHIH-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000005412 pyrazyl group Chemical group 0.000 description 1
- IRNVCLJBFOZEPK-UHFFFAOYSA-N pyridine-2,3,6-triamine Chemical compound NC1=CC=C(N)C(N)=N1 IRNVCLJBFOZEPK-UHFFFAOYSA-N 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 238000007655 standard test method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- VDNNYNILVFHOQX-UHFFFAOYSA-N tert-butyl 4-[2-(4-fluorophenyl)-1-(2-methylsulfanylpyrimidin-4-yl)imidazo[4,5-b]pyridin-5-yl]piperazine-1-carboxylate Chemical compound CSC1=NC=CC(N2C3=CC=C(N=C3N=C2C=2C=CC(F)=CC=2)N2CCN(CC2)C(=O)OC(C)(C)C)=N1 VDNNYNILVFHOQX-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- CFQJBWKKHCMCGJ-UHFFFAOYSA-N tributyl(pyridin-3-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=CN=C1 CFQJBWKKHCMCGJ-UHFFFAOYSA-N 0.000 description 1
- YCBWXJZXFUKDPU-UHFFFAOYSA-N trimethyl(pyridin-4-yl)stannane Chemical compound C[Sn](C)(C)C1=CC=NC=C1 YCBWXJZXFUKDPU-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9925441.9A GB9925441D0 (en) | 1999-10-27 | 1999-10-27 | Organic compounds |
| GB9925441.9 | 1999-10-27 | ||
| GBGB9926173.7A GB9926173D0 (en) | 1999-11-04 | 1999-11-04 | Organic compounds |
| GB9926173.7 | 1999-11-04 | ||
| PCT/EP2000/010528 WO2001030778A1 (en) | 1999-10-27 | 2000-10-25 | Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003512467A true JP2003512467A (ja) | 2003-04-02 |
| JP2003512467A5 JP2003512467A5 (https=) | 2007-12-06 |
Family
ID=26316029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001533132A Pending JP2003512467A (ja) | 1999-10-27 | 2000-10-25 | チアゾールおよびイミダゾ（４，５−ｂ）ピリジン化合物ならびにそれらの医薬用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6608072B1 (https=) |
| EP (1) | EP1224185B1 (https=) |
| JP (1) | JP2003512467A (https=) |
| AR (1) | AR029011A1 (https=) |
| AT (1) | ATE311385T1 (https=) |
| AU (1) | AU7922900A (https=) |
| CO (1) | CO5251463A1 (https=) |
| DE (1) | DE60024480T2 (https=) |
| ES (1) | ES2254238T3 (https=) |
| PE (1) | PE20011039A1 (https=) |
| WO (1) | WO2001030778A1 (https=) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2005016910A1 (ja) * | 2003-08-18 | 2006-10-12 | 富士フイルムファインケミカルズ株式会社 | ピリジルテトラヒドロピリジン類およびピリジルピペリジン類とそれらの製造方法 |
| JP2007518767A (ja) * | 2004-01-21 | 2007-07-12 | ノバルティス アクチエンゲゼルシャフト | Ａ２ｂアンタゴニストとしてのチアゾール誘導体 |
| JP2010538000A (ja) * | 2007-08-27 | 2010-12-09 | シガ・テクノロジーズ・インコーポレーテッド | アレナウイルス感染症を治療するための抗ウイルス薬 |
| JP2011520887A (ja) * | 2008-05-13 | 2011-07-21 | アイアールエム・リミテッド・ライアビリティ・カンパニー | キナーゼ阻害剤としての縮合窒素含有ヘテロ環およびその組成物 |
| JP2012527461A (ja) * | 2009-05-19 | 2012-11-08 | ダウ アグロサイエンシィズ エルエルシー | 真菌を防除するための化合物および方法 |
| JP2016529292A (ja) * | 2013-08-30 | 2016-09-23 | ピーティーシー セラピューティクス， インコーポレイテッド | 置換ピリミジンＢｍｉ−１阻害剤 |
| JP2016539979A (ja) * | 2013-12-09 | 2016-12-22 | ユーシービー バイオファルマ エスピーアールエル | Ｔｎｆ活性のモジュレーターとしてのイミダゾピリジン誘導体 |
| JP2018508554A (ja) * | 2015-03-18 | 2018-03-29 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｎｆ阻害剤として有用な三環式ヘテロ環式化合物 |
| JP2018508553A (ja) * | 2015-03-18 | 2018-03-29 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 置換三環式ヘテロ環式化合物 |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE342892T1 (de) | 1998-08-29 | 2006-11-15 | Astrazeneca Ab | Pyrimidine verbindungen |
| US6632820B1 (en) | 1998-08-29 | 2003-10-14 | Astrazeneca Ab | Pyrimidine compounds |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004886D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
| JP2004503553A (ja) * | 2000-06-14 | 2004-02-05 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | ６，５−縮合二環式複素環 |
| GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| GB0021726D0 (en) | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| US7199124B2 (en) | 2001-02-02 | 2007-04-03 | Takeda Pharmaceutical Company Limited | JNK inhibitor |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
| ATE325608T1 (de) | 2001-08-13 | 2006-06-15 | Janssen Pharmaceutica Nv | 2,4,5-trisubstituted thiazolyl derivative und deren antiinflammatorische wirkung |
| TWI322807B (en) * | 2002-01-07 | 2010-04-01 | Eisai R&D Man Co Ltd | Novel deazapurines and uses thereof |
| DK1474425T3 (da) | 2002-01-07 | 2006-09-25 | Eisai Co Ltd | Deazapuriner og anvendelser deraf |
| GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| US7442697B2 (en) | 2002-03-09 | 2008-10-28 | Astrazeneca Ab | 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity |
| GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| US7361665B2 (en) | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| JP2006500365A (ja) | 2002-08-14 | 2006-01-05 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | ｐ３８ＭＡＰキナーゼインヒビターを用いた抗凝固及び線維素溶解療法 |
| GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| US7468376B2 (en) | 2003-02-27 | 2008-12-23 | Palau Pharma, S.A. | Pyrazolopyridine derivates |
| GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| TWI334868B (en) * | 2003-06-03 | 2010-12-21 | Nippon Kayaku Kk | [1,2,4] triazoro [1,5-a] pyrimidine-2-ylurea derivative and use thereof |
| JP2007500178A (ja) * | 2003-07-30 | 2007-01-11 | サイクラセル・リミテッド | プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体 |
| WO2005070932A2 (en) * | 2004-01-22 | 2005-08-04 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| TWI332003B (en) * | 2004-01-30 | 2010-10-21 | Lilly Co Eli | Kinase inhibitors |
| TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
| US7713998B2 (en) | 2004-11-10 | 2010-05-11 | Ono Pharmaceutical Co., Ltd. | Nitrogenous heterocyclic compound and pharmaceutical use thereof |
| KR100848205B1 (ko) * | 2005-06-20 | 2008-07-24 | 주식회사 동부하이텍 | 면역 억제 및 염증 억제 활성을 갖는 신규한 치환된1,3-티아졸 유도체 또는 이의 약학적으로 허용가능한 염,중간체 화합물 또는 이의 약학적으로 허용가능한 염, 이의제조방법, 및 이를 포함하는 약학적 조성물 |
| WO2007034278A2 (en) * | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | Fused imidazole derivatives as c3a receptor antagonists |
| AR056556A1 (es) | 2005-09-30 | 2007-10-10 | Astrazeneca Ab | Imidazo(1,2-a)piridina con actividad antiproliferacion celular |
| US7968572B2 (en) | 2005-10-03 | 2011-06-28 | Ono Pharmaceuticals Co., Ltd. | Nitrogen-containing heterocyclic compound and pharmaceutical application thereof |
| WO2009076140A1 (en) * | 2007-12-13 | 2009-06-18 | Smithkline Beecham Corporation | Thiazole and oxazole kinase inhibitors |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| EP3623374B1 (en) | 2008-12-03 | 2021-09-08 | The Scripps Research Institute | Stem cell cultures |
| EP2198710A1 (de) | 2008-12-19 | 2010-06-23 | Bayer CropScience AG | Verwendung von 5-Pyridin-4yl-(1,3)Thiazole zur Bekämpfung phytopathogener Pilze |
| SG192941A1 (en) * | 2011-02-25 | 2013-09-30 | Merck Sharp & Dohme | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| CN103145706B (zh) * | 2012-11-16 | 2015-11-25 | 温州医学院 | 一类具有抗炎作用的咪唑并吡啶类化合物及其在制备抗炎药物中的应用 |
| NZ746607A (en) | 2012-11-21 | 2019-11-29 | Ptc Therapeutics Inc | Substituted reverse pyrimidine bmi-1 inhibitors |
| WO2014172639A1 (en) * | 2013-04-19 | 2014-10-23 | Ruga Corporation | Raf kinase inhibitors |
| WO2015076800A1 (en) | 2013-11-21 | 2015-05-28 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine bmi-1 inhibitors |
| CR20170077A (es) | 2014-08-04 | 2017-06-26 | Nuevolution As | Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias |
| US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
| WO2019142128A1 (en) * | 2018-01-18 | 2019-07-25 | Integral Biosciences Private Limited | Dual inhibitors of alk5 and p38α map kinase |
| EP3836932A2 (en) | 2018-08-17 | 2021-06-23 | PTC Therapeutics, Inc. | Method for treating pancreatic cancer |
| MX2021003904A (es) | 2018-10-05 | 2021-10-26 | Annapurna Bio Inc | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj. |
| MX2022007265A (es) | 2019-12-20 | 2022-09-09 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
| UY38994A (es) | 2019-12-20 | 2021-07-30 | Nuevolution As | Compuestos activos frente a receptores nucleares |
| WO2021198956A1 (en) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Compounds active towards nuclear receptors |
| AU2021245397A1 (en) | 2020-03-31 | 2022-10-20 | Nuevolution A/S | Compounds active towards nuclear receptors |
| CA3261365A1 (en) * | 2022-07-28 | 2024-02-01 | Ac Immune Sa | NEW COMPOUNDS |
Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6058981A (ja) * | 1983-09-09 | 1985-04-05 | Takeda Chem Ind Ltd | ５−ピリジル−１，３−チアゾ−ル誘導体，その製造法およびそれを含んでなる医薬組成物 |
| JPH07503018A (ja) * | 1992-01-13 | 1995-03-30 | スミスクライン・ビーチャム・コーポレイション | ピリジル置換イミダゾール |
| WO1996040143A1 (en) * | 1995-06-07 | 1996-12-19 | Smithkline Beecham Corporation | Imidazole compounds |
| JPH09505055A (ja) * | 1993-11-08 | 1997-05-20 | スミスクライン・ビーチャム・コーポレイション | サイトカイン媒介疾患治療用オキサゾール |
| WO1998047899A1 (en) * | 1997-04-24 | 1998-10-29 | Ortho-Mcneil Corporation, Inc. | Substituted pyrrolopyridines useful in the treatment of inflammatory diseases |
| JPH11193281A (ja) * | 1997-10-27 | 1999-07-21 | Takeda Chem Ind Ltd | アデノシンａ３受容体拮抗剤およびチアゾール化合物 |
| JPH11510511A (ja) * | 1995-08-10 | 1999-09-14 | メルク エンド カンパニー インコーポレーテッド | ２，５−置換アリールピロール、この化合物を含有する組成物及び使用方法 |
| JPH11263789A (ja) * | 1998-01-05 | 1999-09-28 | Eisai Co Ltd | プリン誘導体および糖尿病の予防・治療剤としてのアデノシンａ２受容体拮抗剤 |
| WO1999064418A1 (en) * | 1998-06-05 | 1999-12-16 | Novartis Ag | Aryl pyridinyl thiazoles |
| WO2000009506A1 (en) * | 1998-08-12 | 2000-02-24 | Hokuriku Seiyaku Co., Ltd. | 1h-imidazopyridine derivatives |
| JP2001114779A (ja) * | 1999-04-23 | 2001-04-24 | Takeda Chem Ind Ltd | ５−ピリジル−１，３−アゾール化合物、その製造法及び用途 |
| JP2001506239A (ja) * | 1996-12-11 | 2001-05-15 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
| JP2001506280A (ja) * | 1997-06-30 | 2001-05-15 | ノバルティス アクチエンゲゼルシャフト | ２−置換４，５−ジアリールイミダゾール |
| JP2001506980A (ja) * | 1996-11-19 | 2001-05-29 | アムジエン・インコーポレーテツド | アリールおよびヘテロアリール置換縮合ピロール抗炎症剤 |
| JP2001520227A (ja) * | 1997-10-20 | 2001-10-30 | エフ．ホフマン−ラ ロシュ アーゲー | 二環式キナーゼ阻害剤 |
| JP2003503311A (ja) * | 1999-04-14 | 2003-01-28 | ノバルティス アクチエンゲゼルシャフト | 置換アゾール類 |
| JP2003520197A (ja) * | 1999-05-14 | 2003-07-02 | メルク エンド カムパニー インコーポレーテッド | サイトカイン阻害活性をもつ化合物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5739143A (en) * | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
| DE60033028T2 (de) * | 1999-04-23 | 2007-11-15 | Takeda Pharmaceutical Co. Ltd. | 5-pyridyl-1,3-azol-derivate, verfahren zu ihrer herstellung und ihre verwendung |
-
2000
- 2000-10-25 AU AU79229/00A patent/AU7922900A/en not_active Abandoned
- 2000-10-25 WO PCT/EP2000/010528 patent/WO2001030778A1/en not_active Ceased
- 2000-10-25 AT AT00969551T patent/ATE311385T1/de not_active IP Right Cessation
- 2000-10-25 DE DE60024480T patent/DE60024480T2/de not_active Expired - Lifetime
- 2000-10-25 JP JP2001533132A patent/JP2003512467A/ja active Pending
- 2000-10-25 EP EP00969551A patent/EP1224185B1/en not_active Expired - Lifetime
- 2000-10-25 US US10/111,233 patent/US6608072B1/en not_active Expired - Fee Related
- 2000-10-25 ES ES00969551T patent/ES2254238T3/es not_active Expired - Lifetime
- 2000-10-26 AR ARP000105643A patent/AR029011A1/es unknown
- 2000-10-26 PE PE2000001147A patent/PE20011039A1/es not_active Application Discontinuation
- 2000-10-27 CO CO00082019A patent/CO5251463A1/es not_active Application Discontinuation
-
2003
- 2003-06-23 US US10/601,690 patent/US6891039B2/en not_active Expired - Fee Related
Patent Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6058981A (ja) * | 1983-09-09 | 1985-04-05 | Takeda Chem Ind Ltd | ５−ピリジル−１，３−チアゾ−ル誘導体，その製造法およびそれを含んでなる医薬組成物 |
| JPH07503018A (ja) * | 1992-01-13 | 1995-03-30 | スミスクライン・ビーチャム・コーポレイション | ピリジル置換イミダゾール |
| JPH09505055A (ja) * | 1993-11-08 | 1997-05-20 | スミスクライン・ビーチャム・コーポレイション | サイトカイン媒介疾患治療用オキサゾール |
| WO1996040143A1 (en) * | 1995-06-07 | 1996-12-19 | Smithkline Beecham Corporation | Imidazole compounds |
| JPH11510511A (ja) * | 1995-08-10 | 1999-09-14 | メルク エンド カンパニー インコーポレーテッド | ２，５−置換アリールピロール、この化合物を含有する組成物及び使用方法 |
| JP2001506980A (ja) * | 1996-11-19 | 2001-05-29 | アムジエン・インコーポレーテツド | アリールおよびヘテロアリール置換縮合ピロール抗炎症剤 |
| JP2001506239A (ja) * | 1996-12-11 | 2001-05-15 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
| WO1998047899A1 (en) * | 1997-04-24 | 1998-10-29 | Ortho-Mcneil Corporation, Inc. | Substituted pyrrolopyridines useful in the treatment of inflammatory diseases |
| JP2001506280A (ja) * | 1997-06-30 | 2001-05-15 | ノバルティス アクチエンゲゼルシャフト | ２−置換４，５−ジアリールイミダゾール |
| JP2001520227A (ja) * | 1997-10-20 | 2001-10-30 | エフ．ホフマン−ラ ロシュ アーゲー | 二環式キナーゼ阻害剤 |
| JPH11193281A (ja) * | 1997-10-27 | 1999-07-21 | Takeda Chem Ind Ltd | アデノシンａ３受容体拮抗剤およびチアゾール化合物 |
| JPH11263789A (ja) * | 1998-01-05 | 1999-09-28 | Eisai Co Ltd | プリン誘導体および糖尿病の予防・治療剤としてのアデノシンａ２受容体拮抗剤 |
| WO1999064418A1 (en) * | 1998-06-05 | 1999-12-16 | Novartis Ag | Aryl pyridinyl thiazoles |
| WO2000009506A1 (en) * | 1998-08-12 | 2000-02-24 | Hokuriku Seiyaku Co., Ltd. | 1h-imidazopyridine derivatives |
| JP2003503311A (ja) * | 1999-04-14 | 2003-01-28 | ノバルティス アクチエンゲゼルシャフト | 置換アゾール類 |
| JP2001114779A (ja) * | 1999-04-23 | 2001-04-24 | Takeda Chem Ind Ltd | ５−ピリジル−１，３−アゾール化合物、その製造法及び用途 |
| JP2003520197A (ja) * | 1999-05-14 | 2003-07-02 | メルク エンド カムパニー インコーポレーテッド | サイトカイン阻害活性をもつ化合物 |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2005016910A1 (ja) * | 2003-08-18 | 2006-10-12 | 富士フイルムファインケミカルズ株式会社 | ピリジルテトラヒドロピリジン類およびピリジルピペリジン類とそれらの製造方法 |
| US8530662B2 (en) | 2003-08-18 | 2013-09-10 | Fujifilm Finechemicals Co., Ltd | Pyridyltetrahydropyridines and pyridylpiperidines, and method of manufacturing them |
| JP2007518767A (ja) * | 2004-01-21 | 2007-07-12 | ノバルティス アクチエンゲゼルシャフト | Ａ２ｂアンタゴニストとしてのチアゾール誘導体 |
| JP2010538000A (ja) * | 2007-08-27 | 2010-12-09 | シガ・テクノロジーズ・インコーポレーテッド | アレナウイルス感染症を治療するための抗ウイルス薬 |
| JP2011520887A (ja) * | 2008-05-13 | 2011-07-21 | アイアールエム・リミテッド・ライアビリティ・カンパニー | キナーゼ阻害剤としての縮合窒素含有ヘテロ環およびその組成物 |
| JP2012527461A (ja) * | 2009-05-19 | 2012-11-08 | ダウ アグロサイエンシィズ エルエルシー | 真菌を防除するための化合物および方法 |
| JP2016529292A (ja) * | 2013-08-30 | 2016-09-23 | ピーティーシー セラピューティクス， インコーポレイテッド | 置換ピリミジンＢｍｉ−１阻害剤 |
| JP2016539979A (ja) * | 2013-12-09 | 2016-12-22 | ユーシービー バイオファルマ エスピーアールエル | Ｔｎｆ活性のモジュレーターとしてのイミダゾピリジン誘導体 |
| JP2018508554A (ja) * | 2015-03-18 | 2018-03-29 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｎｆ阻害剤として有用な三環式ヘテロ環式化合物 |
| JP2018508553A (ja) * | 2015-03-18 | 2018-03-29 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 置換三環式ヘテロ環式化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001030778A1 (en) | 2001-05-03 |
| US6608072B1 (en) | 2003-08-19 |
| US6891039B2 (en) | 2005-05-10 |
| CO5251463A1 (es) | 2003-02-28 |
| ES2254238T3 (es) | 2006-06-16 |
| EP1224185B1 (en) | 2005-11-30 |
| AU7922900A (en) | 2001-05-08 |
| DE60024480T2 (de) | 2006-07-27 |
| EP1224185A1 (en) | 2002-07-24 |
| US20040082604A1 (en) | 2004-04-29 |
| PE20011039A1 (es) | 2001-10-30 |
| AR029011A1 (es) | 2003-06-04 |
| ATE311385T1 (de) | 2005-12-15 |
| DE60024480D1 (de) | 2006-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003512467A (ja) | チアゾールおよびイミダゾ（４，５−ｂ）ピリジン化合物ならびにそれらの医薬用途 | |
| JP2001506280A (ja) | ２−置換４，５−ジアリールイミダゾール | |
| US5475008A (en) | Quinolone derivatives | |
| KR20010108504A (ko) | 치환 아졸 | |
| JP2003512467A5 (https=) | ||
| JP2000508334A (ja) | ピラジノン系トロンビン阻害薬 | |
| JP4482513B2 (ja) | Ｎ２−（置換アリールメチル）−３−（置換フェニル）インダゾールおよびこれを含む抗血管形成剤 | |
| JPWO2003037862A1 (ja) | アミド誘導体及び医薬 | |
| WO2003074525A1 (fr) | Compose heterocyclique azote | |
| WO2002022598A1 (en) | Quinolinone derivatives as tyrosine kinase inhibitors | |
| NZ521386A (en) | Substituted beta-carbolines with lkB-kinase inhibiting activity | |
| JP2001514227A (ja) | ピラジノン系トロンビン阻害薬 | |
| AU2001293275A1 (en) | Quinolinone derivatives as tyrosine kinase inhibitors | |
| WO2023232069A1 (zh) | 一种氮杂喹啉酮类衍生物、其制备方法及用途 | |
| JP2002527435A (ja) | 新規なヘテロシクリル−メチル置換ピラゾール類 | |
| JP2001505567A (ja) | 心臓循環系疾患の処置のための新規な置換ピラゾール誘導体 | |
| US5426106A (en) | Pyrrolo-pyridazinone derivatives | |
| CN106715426A (zh) | 氰基取代的咪唑并[1,2‑a]吡啶甲酰胺及其用途 | |
| JPWO2005012258A1 (ja) | タンパク質キナーゼ阻害剤 | |
| AU2005315849B2 (en) | Pyrazolo-heteroaryl compounds useful to treat TNF-Alpha and IL-1 mediated diseases | |
| MX2007005340A (es) | Novedosas piridinurea nicotinamidas como inhibidores de quinasas de receptores del factor de crecimiento del endotelio vascular (vegf). | |
| ES2259704T3 (es) | Compuestos benzoilicos. | |
| TW517052B (en) | 2-substituted 1,2-benzoisonthiazole derivatives, their preparation and use | |
| WO2005100341A1 (ja) | ２－アミノピリミジン誘導体 | |
| JP5113751B2 (ja) | ｐ３８キナーゼ阻害剤として有用な二環性複素環化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071018 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071018 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100908 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100914 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110222 |